{"filings":[{"id":70684,"accession_number":"0001720420-26-000014","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2026-05-13T21:20:00+00:00","items":["8.01","9.01"],"status":"ready","headline":"IBEX Limited authorizes $20M share repurchase program over 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $20M share repurchase starting May 14, 2026, over one year.","Repurchases may be made via open market, negotiated transactions, or block trades, subject to SEC rules.","Company expects to fund repurchases with existing cash and free cash flow; program may be suspended anytime.","CEO Bob Dechant cited confidence in business strength and growth trajectory as rationale.","Repurchase program is part of capital allocation strategy that prioritizes investments for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94970,"accession_number":"0001720420-26-000010","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IBEX reports record Q3 revenue $164.4M (+17%), raises FY guidance third time","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Diluted EPS $0.89 (up 22% YoY); adjusted EPS $0.91 (up 11%).","HealthTech revenue grew 53.7%, Technology +42.6%, Travel/Logistics +15.1%, Retail/E-commerce +8.3%.","Adjusted EBITDA record $22.0M; raised FY revenue guidance to $638-642M and Adj. EBITDA to $82-84M.","Announced strategic partnership with Sierra AI to integrate AI-powered CX solutions.","Repurchased 140,300 shares for $4.5M in quarter; net cash $14.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":479807000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107730,"accession_number":"0001720420-26-000005","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IBEX reports record Q2 revenue $164.2M (+17% YoY), raises FY revenue & EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $164.2M (+16.7% YoY); net income $12.2M; diluted EPS $0.83 (+45% YoY).","Adjusted EBITDA $20.7M (+25.2% YoY); adjusted EPS $0.87 (+46% YoY).","Raises FY2026 revenue guidance to $620-630M (from $605-620M) and adjusted EBITDA to $80-82M (from $78-81M).","HealthTech revenue grew 35.1% YoY; repurchased 78,200 shares for $2.9M during quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":315400000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124101,"accession_number":"0001720420-25-000054","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ibex appoints Shuja Keen to board, John Jones as Chair, Mingzhe Zhuang as Lead Independent Director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shuja Keen reappointed to fill board vacancy; previously served from March 2018 through December 2024.","John Jones appointed Chair of Board (non-independent); Mingzhe Zhuang appointed Lead Independent Director and Chair of Corporate Governance Committee.","Board changes responsive to previously received shareholder feedback on governance structure.","Keen will participate in Company's standard non-executive director compensation program; appointments effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124100,"accession_number":"0001720420-25-000050","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.07","5.02"],"status":"ready","headline":"Ibex shareholder meeting passes all proposals; nominee Khaishgi withdraws","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual meeting held Dec 5, 2025; all five shareholder proposals approved.","Proposal 2: Seven directors elected; highest vote count 10.1M (Batungbacal), lowest 8.95M (Jones).","Proposal 4: Amended 2020 LTIP approved with 9.43M for, 0.74M against.","Proposal 5: Deloitte & Touche LLP ratified as auditor for FY2026.","Director nominee Mohammed Khaishgi withdrew before election for personal reasons; board vacancy remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124099,"accession_number":"0001720420-25-000042","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IBEX Limited establishes formal Nominating Committee to address ISS/Glass Lewis concerns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board formed Nominating Committee on Nov 20, 2025; Chair Daniella Ballou-Aares, members Batungbacal, Beck, McGinnis, Zhuang.","Committee ratified prior year actions and renominated director slate for Dec 5, 2025 annual meeting.","Actions respond to ISS and Glass Lewis proxy recommendations about deficiencies in the nominating process.","Committee and full Board unanimously recommend a vote 'FOR' each director nominee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124098,"accession_number":"0001720420-25-000039","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IBEX Q1 revenue $151.2M (+16.5% YoY); EPS $0.82 (+91%), raises FY 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $151.2M (+16.5% YoY); net income $12.0M (+59.9%); diluted EPS $0.82 vs $0.43.","Adjusted EPS $0.90 (+74%); adjusted EBITDA $19.5M (+24.9%); margin 12.9% vs 12.0%.","Raised FY2026 guidance: revenue to $605-620M (from $590-610M); Adj. EBITDA to $78-81M.","Free cash flow $8.0M vs $4.1M; repurchased 91,658 shares for $2.7M during quarter.","Growth driven by Retail & E-commerce (+25%), HealthTech (+19.5%), and Travel (+15.4%)."],"consensus_eps_estimate":0.8721,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":151179000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140760,"accession_number":"0001720420-25-000026","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IBEX reports record Q4 revenue up 18.2%, FY adjusted EPS $2.75, introduces FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $147.1M (+18.2% YoY); FY revenue $558.3M (+9.8% YoY), both records.","Q4 adjusted EPS $0.87 (+50% YoY); FY adjusted EPS $2.75 (+31% YoY).","Record FY free cash flow $27.3M; Q4 free cash flow $22.8M (best ever quarter).","FY2026 guidance: revenue $590-610M, adjusted EBITDA $75-79M; Q1 rev $143-146M.","Repurchased ~3.9M shares in FY2025 (23% of outstanding), eliminating controlled company status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158501,"accession_number":"0001628280-25-023828","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"IBEX reports record Q3 revenue $140.7M (+11% YoY), raises FY guidance, authorizes $15M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $140.7M, +11% YoY; adjusted EPS $0.82 (+18% YoY), both quarterly records.","GAAP diluted EPS $0.73 vs $0.57; net income $10.5M (+1.5%).","Raised FY2025 revenue guidance to $540-545M (prev. $525-535M); adj. EBITDA $68-70M.","Board authorized $15M share repurchase plan starting May 12, 2025.","Strategic entry into India with a healthcare client; 4 new logo wins in Q3."],"consensus_eps_estimate":0.7497,"consensus_eps_actual":1.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":411135000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176888,"accession_number":"0001720420-25-000008","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IBEX Q2 revenue $140.7M (+6.1% YoY); raises FY guidance; adjusted EPS $0.59","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $140.7M (+6.1% YoY); net income $9.3M (+52.6%); diluted EPS $0.57 vs $0.33 a year ago.","Adjusted EPS $0.59 (+36% YoY); adjusted EBITDA $16.5M (+15.4%); margin 11.8% vs 10.8%.","Raised FY2025 revenue guidance to $525-535M (from $515-525M); adjusted EBITDA guidance $68-69M.","Repurchased 3.6M shares from TRGI for $70M, eliminating controlled company status.","HealthTech (+31.2%) and Travel/T&L (+16.7%) drove growth; FinTech declined 14.7%."],"consensus_eps_estimate":0.714,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":270399000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176887,"accession_number":"0001720420-25-000004","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"IBEX pays off $25M convertible note from TRGI share repurchase using HSBC credit lines","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Jan 9, 2025, IBEX paid in full the $25M convertible promissory note issued to TRGI on Nov 19, 2024.","The Seller Note was terminated following payment, eliminating potential dilution from conversion.","Payment funded through drawings on HSBC credit lines (HSBC Bank USA and HSBC Bank ME).","The original share repurchase on Nov 19, 2024 was 3,562,341 shares for $70M ($45M cash + $25M note)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176886,"accession_number":"0001720420-25-000002","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IBEX appoints Karen Batungbacal to board; Shuja Keen retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Batungbacal appointed independent director, effective Jan 20, 2025; brings CX expertise from JPMorgan Chase, UnitedHealth Group.","Shuja Keen retired from board Dec 31, 2024; to advise on AI initiatives via AI Advisory Committee.","Five TRGI-designated directors (Dechant, Ballou-Aares, Zhuang, McGinnis, Jones) reappointed after TRGI revocation; board now has eight directors, five independent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193698,"accession_number":"0001720420-24-000064","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"IBEX Limited shareholders elect directors, approve auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved setting maximum number of directors at eight with 14,255,011 votes for and 20,629 against.","Directors Fiona Beck, Shuja Keen, and Mohammed Khaishgi were elected; Beck received 12,696,211 votes for.","Appointment of Deloitte & Touche LLP as auditor for fiscal 2025 approved with 14,272,942 votes for and 2,697 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193697,"accession_number":"0001628280-24-048601","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"IBEX repurchases 3.56M shares from controlling shareholder TRGI for $70M, exits controlled company status","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 3,562,341 shares at $19.65 each from TRGI, representing ~20% of diluted shares outstanding.","Total consideration $70M: $45M cash plus $25M convertible promissory note bearing 7% annual interest.","Following repurchase, TRGI retains 1.8M shares; IBEX will no longer be a Nasdaq-controlled company.","Board to have majority independent directors; one TRGI director to resign by year-end, others serve until 2025 AGM.","Company holds 4-year call option to buy remaining TRGI shares upon change of control; existing share buyback program paused."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193696,"accession_number":"0001720420-24-000061","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IBEX reports record Q1 FY25 revenue $129.7M, adj. EBITDA margin 12.0%, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $129.7M (+4.1% YoY); diluted EPS $0.43 (+9.6% YoY).","Adjusted EBITDA $15.6M (+13.7%); adjusted EPS $0.52 (+28.9% YoY).","HealthTech +23.4%, Retail & E-commerce +8.6%; FinTech declined 13.0%.","Repurchased ~282k shares for $4.7M; ended quarter with $60.8M net cash.","FY2025 revenue guidance raised to $515-525M (from $510-525M); adj. EBITDA $67-69M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":129717000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193695,"accession_number":"0001140361-24-045075","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Ibex Limited enters $75M credit facilities with HSBC, replacing $80M PNC facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M US secured revolving facility with HSBC Bank USA; SOFR+2% or ABR+1%.","$50M UAE committed revolving loan facility with HSBC Bank Middle East; 3-month SOFR+2%.","Existing $80M PNC Bank secured revolving facility terminated and repaid in full on Oct 29, 2024.","Proceeds to repay existing facility, fund working capital, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193694,"accession_number":"0001720420-24-000054","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"IBEX appoints McGinnis and Zhuang to board; Leone and Kleisterlee exit","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Leone resigned effective Oct 24; Gerard Kleisterlee to retire after Dec 5 AGM.","Fiona Beck appointed to board and Audit Committee Chair, filling Leone's vacancy.","Patrick McGinnis (venture capitalist) appointed effective Oct 24, 2024.","JJ Zhuang (ex-Instacart chief architect) appointed effective after 2024 AGM.","Retirements are not related to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209995,"accession_number":"0001720420-24-000040","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IBEX Q4 rev $124.5M, net income up 118% YoY; FY2024 record EPS $1.84; guides FY2025 rev $510-525M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $124.5M (flat YoY); net income $9.8M (+118%); diluted EPS $0.56 (+133%).","FY2024 revenue $508.6M (-2.8% YoY); net income $33.7M (+6.6%); diluted EPS $1.84 (+10.2%).","Record adjusted EBITDA margin 12.8%; free cash flow $27.0M (up 18%); repurchased 1.3M shares for $21.7M.","FY2025 guidance: revenue $510-525M; adjusted EBITDA $67-69M; Q1 revenue $124-126M; capex $15-20M.","Won 18 new client relationships (vs 10 prior year); closed first significant customer-facing AI opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228206,"accession_number":"0001720420-24-000030","cik":1720420,"company_name":"IBEX Ltd","ticker":"IBEX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"IBEX reports Q3 FY2024 record adjusted EBITDA margin 15.1%, adj EPS $0.70; announces $30M share repurchase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $126.8 million (-3.6% YoY); net income $10.3M ($0.57 diluted EPS) vs $11.3M ($0.59) prior year.","Adjusted EBITDA $19.2M (record 15.1% margin); adjusted EPS $0.70 (record).","Won 3 new clients in Q3, bringing YTD total to 15 vs 8 in prior YTD period.","Board authorized up to $30M share repurchase over next 12 months, funded from existing cash."],"consensus_eps_estimate":null,"consensus_eps_actual":1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":384038000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":424033321.27033114,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}